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Parkinson’s Disease is a neurodegenerative 
disease that is pathologically characterized by 
abnormal α-synuclein protein aggregation, 
dopamine depletion in nigrostriatal neurons, and 
the subsequent death of these neurons. Oxidative 
stress has been widely implicated as a cause for 
neurodegenerative diseases, especially Parkinson’s 
Disease (PD). The mechanisms by which oxidative 
stress occurs in PD neurons and causes cell death 
remain obscure. Recent research has revealed 
several mechanisms by which α-synuclein and 
oxidative stress may induce cell death in PD, 
providing potential targets for therapies. The roles 
of α-synuclein, PD-inducing drugs, and DJ-1 as well 
as their involvement in oxidative stress production 




Parkinson’s disease (PD) is a progressive 
neurodegenerative disorder that afflicts one million 
people in the U.S., and four million people worldwide. It 
is characterized by resting tremors, postural instability, 
and bradykinesia (Olanow and Tatton, 1999)—all 
symptoms which result from the death of dopamine 
producing neurons in the substantia nigra pars 
compacta. Although five percent of PD cases result 
from genetic mutations in one of several key genes, 
ninety-five percent of PD cases are sporadic. This 
review explores oxidative stress as a contributor to 
sporadic PD.  
Reactive oxygen species (ROS), such as 
superoxide, hydrogen peroxide, and the hydroxyl 
radical, are reactive molecules that cause cellular 
stress. Mitochondria can generate ROS within the cell 
during normal metabolic reactions, and these free 
radicals can significantly damage other cellular 
structures, including lipid membranes, proteins in 
important cellular machinery, and DNA. In PD patients, 
increased lipid peroxidation (Dexter et al., 1986), protein 
carbonylation (Alam et al., 1997a), and oxidation of 
DNA (Alam et al., 1997b) have all been detected in the 
substantia nigra, implying the occurrence of oxidative 
stress within these neurons. The inhibition of complex I 
of the mitochondria has been shown to generate ROS, 
which can damage the electron-transport chain and 
lead to further production of ROS (Dauer and 
Przedborski, 2003). Several studies have confirmed the 
deficiency of complex I in the brains of PD patients 
(Schapira et al., 1989; Mizuno et al., 1989; Parker et al., 
1989), and the death of dopaminergic neurons has 
been shown to increase when complex I of the 
mitchondria is deficient (Kweon et al., 2004). These  
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markers of oxidative stress have led to research aiming 
to discover the mechanisms behind oxidative stress 
and cell death in PD. 
 
Modeling PD with drugs 
 
Several molecular species and drugs are thought to 
lead to the onset of PD and have been used to 
successfully produce Parkinsonism in model 
organisms.  Dopamine, itself, is thought to be the single 
most important species that contributes to oxidative 
stress conditions in the brains of PD patients. While this 
neurotransmitter is the molecular species that enables 
neuronal activity, its oxidized metabolites can act as 
endogenous neurotoxins within these neurons 
(Hastings and Zigmond, 1997).  Dopamine can undergo 
auto-oxidation and form reactive dopamine quinones or 
6-hydroxydopamine (6-OHDA), which can generate the 
deleterious hydroxyl radical and hydrogen peroxide 
species (Heikkila and Cohen, 1973; Slivka and Cohen, 
1985). 6-OHDA induces nirgostriatal neuronal death in 
rats (Mendez and Finn, 1975; Javoy et al., 1976) and 
human neuroblastoma (Simantov et al., 1996). Because 
dopamine depletion is a common pathology of PD, 
therapies, such as L-dopa, have aimed to replace 
dopamine within surviving neurons in order to restore 
their function, thus reducing the symptoms of PD. 
Although L-dopa, which was first used in the 1960s, is 
effective in restoring nigrostriatal function, its long term 
effects are now under investigation because L-dopa is 
converted to dopamine in the patient, and which can 
then undergo auto-oxidation and form toxic species.  
The connection between oxidative stress and 
PD has also been strengthened by the effects of 
several drugs on nigrostriatal dopaminergic neurons. 
The drug MPTP has been shown to cause extensive 
dopaminergic neuronal death in the substantia nigra, 
leading to Parkinson’s Disease. This drug has been 
used to model PD in animals and has revealed findings 
such as parkinsonism in non-human primates (Burns et 
al., 1983) as well as the loss of movement in mice 
(Sundstrom et al., 1990), rats (Sahgal et al., 1984), and 
zebrafish (Bretaud et al., 2004). When this drug is 
oxidized to its metabolite, MPP+, it inhibits 
mitochondrial respiration by blocking the flow of 
electrons in complex I (Ramsay et al., 1991), leading to 
increased levels of ROS (Singer et al., 1987). Because 
MPTP causes oxidative stress and PD, examining its 
effects in model organisms may elucidate mechanisms 
that show oxidative stress is a precursor or result of PD. 
Rotenone is another complex I inhibitor that 
has been used to model PD in rats (Betarbet et al., 
2000) and Drosophila (Coulom et al., 2004). It has been 
shown to induce apoptosis at low concentrations in 
neuronal PC-12 cells (Hartley et al., 1994) and to 
increase oxidative stress conditions, increase α-
synuclein accumulation, and induce apoptosis in human 
neuroblastoma (Sherer et al., 2002). Another molecule, 
paraquat, is an oxidative herbicide that has also been 
used to model PD. It was first shown to cause 
neurodegeneration in rats (Corasaniti et al., 1992) and 
has since been shown to cause apoptosis in PC-12 
cells (Li and Sun, 1999) and dopaminergic cell loss in 
mice (Brooks et al., 1999). The mechanisms by which 
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6-OHDA, MPTP, rotenone, and paraquat cause cell 
death are only partially understood. Both MPP+ and 
rotenone bind to either the same or adjacent sites in 
complex I of the mitochondria to inhibit mitochondrial 
respiration (Ramsay et al., 1999; Krueger et al., 1990), 
indicating that they induce neuronal death via similar 
mechanisms. In addition, MPP+ is transported into cells 
via the dopamine transporter (DAT), accounting for its 
selectivity in targeting dopaminergic neurons (Kitayama 
et al., 1992; Kitayama et al., 1993). On the other hand, 
one study has shown that, while MPP+ causes cell 
death via inhibition of mitochondrial complex I, 6-OHDA 
apoptosis occurs independent of mitochondrial 
impairment (Wu et al., 1996).  
Most recent studies have shown a 
relationship between 6-OHDA neurotoxicity and 
cyclooxygenase (COX) activity (Carrasco et al., 2005). 
COX is an enzymatic mediator of inflammation 
(McDaniel et al., 1996) that has been found at 
increased levels in the dopaminergic neurons of PD 
patients (Knott et al., 2000). Regular use of non-
steroidal anti-inflammatory drugs, such as ibuprofen, 
has been shown to reduce the risk of PD (Casper et al., 
2000; Chen et al., 2005). A recent study has shown that 
ibuprofen, a non-selective inhibitor of COX activity, 
attenuated the death of embryonic rat mesencephalic 
neurons by 6-OHDA, but not MPP+ (Carrasco et al., 
2005). Furthermore, a specific inhibitor of COX-2 was 
shown to decrease 6-OHDA toxicity, while no 
correlation was shown for COX-1. This study further 
supports that, in addition to the ability to generate ROS, 
6-OHDA could be involved in a toxic mechanism that is 
seemingly independent of oxidative stress conditions.  
While rotenone is a well-studied complex I 
inhibitor, it has recently been shown to be involved in 
an apoptotic pathway. Bcl-2 is a protein that prevents 
apoptosis induced by the fas cell death receptor 
(Jaattela et al., 1995), and BAD is a protein that blocks 
the activity of Bcl-2, thereby causing cell death (Yang et 
al., 1995). Rotenone has been shown to 
dephosphorylate the BAD protein in human 
dopaminergic SH-SY5Y cells, an event that allows BAD 
to block Bcl-2 (Watabe and Nakaki, 2004). Both 
rotenone’s involvement in the Bcl-2 pathway and 6-
OHDA’s involvement in COX activity present evidence 
that these PD-inducing agents may cause neuronal 
toxicity via apoptotic pathways not only by contributing 
to oxidative stress conditions. This suggests that these 
species may have dual roles in causing PD. Further 
studies may someday link these toxic species’ 
involvement in apoptosis to oxidative stress, as 
mitochondria are primary producers of ROS and are 
involved in the initiation of apoptotic pathways. 
Fortunately, cells are equipped with machinery to 
combat the ROS that can lead to untimely cell death. 
 
Oxidative stress enzymes and PD 
 
Over the course of evolution, cells have constructed 
enzymatic machinery to combat oxidative stress. For 
example, superoxide dismutase (SOD) is an enzyme 
that catalyzes the reaction of the superoxide radical 
(O2·-) to hydrogen peroxide and molecular oxygen (O2). 
This enzyme is a protein complex that can have various 
types of metal ion content (mangansese, copper-zinc, 
and iron). Manganese superoxide dismutase (SOD2) is 
found in the matrix of mitochondria (Slot et al., 1986), 
which is the sight of oxidative phosphorylation. 
Theoretically, an antioxidant defense system would be 
required in this area of the cell since the normal 
process of oxidative phosphorylation can give rise to 
superoxide radicals. Copper-zinc superoxide dismutase 
(SOD1) is located in the cytosol and comprises a rather 
large fraction of a cell’s total protein (10µM in yeast) 
(Rae et al., 1999), while iron superoxide dismutase 
(SOD3) is extracellular. Catalase and glutathione are 
two other antioxidant enzymes that catalyze the 
reaction of hydrogen peroxide to molecular oxygen and 
water, thereby reducing a major source of oxidative 
stress. All of these enzymes have been shown to confer 
protection of neurons against oxidative stress. 
SODs, specifically, have been examined in 
many studies of neurodegeneration. Perhaps the best 
known example is the role of SOD1 in amyotrophic 
lateral sclerosis (ALS), also known as Lou Gherig’s 
disease. Twenty percent of familial ALS cases are 
caused by mutations in the SOD1 gene, which causes 
abnormal SOD1 protein aggregation (Rosen et al., 
1993). SOD1 has also been shown to alleviate Aβ 
toxicity by scavenging free radicals generated by the 
abberant Alzheimer’s protein (Bowling and Beal, 1995). 
Moreover, both SOD1 and SOD2 are upregulated in 
neuronal regions containing neurofibrillary tangles and 
plaques in AD patients (Delacourte et al., 1988).  
Many studies have also examined the roles 
of SODs in the protection against oxidative stress in 
PD. Because SOD2 is the major free radical scavenger 
in mitochondria, the SOD2 gene has been closely 
examined in many studies in an attempt to find a 
possible link between the gene and genetic PD cases; 
however, no such correlation has been identified (Jones 
et al., 1998; Farin et al., 2001). But because SOD2 is 
an essential enzyme against mitochondrial oxidative 
stress, SOD2 knockouts have been used as a model of 
endogenous oxidative stress (Hinerfeld et al., 2004). 
Moreover, MPTP-treated mice are more susceptible to 
striatal lesions and dopamine depletion when SOD2 is 
partially deficient (Andreassen et al., 2001). 
Interestingly, SOD2 was also identified as a gene that 
protected against α-synuclein toxicity to yeast cells 
expressing the α-synuclein protein (Willingham et al., 
2003). By delineating the activity of oxidative stress 
enzymes in protecting model organisms from cell death 
under PD-inducing conditions, the role of oxidative 
stress in PD is strengthened. In a genetic cause of PD, 
this relationship between cell death and oxidative stress 
becomes more apparent. 
 
 
Genetic Evidence of Oxidative Stress in PD 
 
A familial mutation and the deletion of the DJ-1 gene 
have been shown to induce autosomal, recessive, 
early-onset PD (Bonifati et al., 2003). DJ-1 is an 
antioxidant protein that eliminates hydrogen peroxide 
by undergoing auto-oxidation (Taira et al., 2004). 
Neuroblastoma cells with DJ-1 knockdown by siRNA 
are susceptible to death by 6-OHDA, hydrogen 
peroxide, and MPP+, all Parkinson’s inducing agents 
(Taira et al., 2004). Moreover, DJ-1 overexpression 
protects cultured primary dopamine neurons and rat 
dopaminergic neurons from hydrogen peroxide and 6-
OHDA induced death by the upregulation of glutathione 
levels (Zhou and Freed, 2005). Another study has 
shown that the knockdown of DJ-1 or the expression of 
mutant DJ-1 in a mouse cell line resulted in the 
downregulation of extracellular iron-SOD expression 
(Nishinaga et al., 2005), suggesting that normal DJ-1 
can regulate gene expression to protect against cell 






Figure 1: α-synuclein, oxidative stress, and DJ-1 involvement in the JNK pathway may explain cell death in PD. 
Several studies support the involvement of the JNK apoptotic pathway in the cell death observed in PD. α-Synuclein is can bind to the JNK-
interacting protein (JIP) to inactivate JNK and prevent apoptosis. DJ-1 can bind to Daxx and prevent its association with the fas death 
receptor, inactivating the JNK pathway and also preventing apoptosis. Rotenone can dephosphorylate BAD, which blocks Bcl-2 from 
inactivating the JNK pathway, thereby causing apoptosis. 
 
presents significant genetic evidence that implicates 
oxidative stress as a cause of PD. 
 DJ-1 has many other functions in addition to 
its ability to quench ROS. A recent study has revealed 
that DJ-1 binds to the Daxx protein (Junn et al., 2005), 
a protein that binds to a fas death receptor (Yang et al., 
1997) and activates the JNK (c-Jun N-terminal kinase) 
apoptotic pathway.  Junn and colleagues discovered 
that when DJ-1 binds to Daxx, it sequesters the protein 
into the nucleus and prevents it from gaining access to 
the cytoplasm and from inducing apoptosis at the fas 
death receptor. Interestingly, Daxx upregulation occurs 
in cells that are treated with the oxidant hydrogen 
peroxide (Kim et al., 2005), linking oxidative stress to 
the activation of this apoptotic pathway. These studies 
together show that DJ-1 is involved in inactivating the 
apoptotic JNK pathway that is activated by oxidative 
stress, indicating its indirect role in guarding against 
oxidative stress-induced cell death (Figure 1).  
 
α-Synuclein and Oxidative Stress 
 
The common pathological hallmark among 
most cases of PD is the accumulation of misfolded α-
synuclein protein into aggregates called Lewy Bodies 
(Spillantini et al., 1997). A connection between a-
synuclein misfolding and oxidative stress has yet to be 
fully established. α-Synuclein has been shown to bind  
 
phospholipids in several in vitro and in vivo studies 
(Davidson et al., 1998; Sharon et al., 2001; Eliezer et 
al., 2001; Outeiro and Lindquist, 2003), and lipid 
peroxidation has been observed in dopaminergic 
neurons within the brains of PD patients. If lipid content 
is damaged within dopaminergic neurons, α-synuclein 
may be unable to bind to the membrane and will 
accumulate within the cytoplasm (Figure 2), accounting 
for the formation of Lewy bodies. 
An emerging theory of α-synuclein toxicity 
conversely proposes that toxic events occur with 
increased binding of α-synuclein protofibrils to the lipid 
membrane (Volles et al., 2001). This study shows that 
in contrast to monomeric and oligomeric forms of α-
synuclein, protofibrillar forms bind more tightly to 
vesicles, permeating and destroying them. This 
provides evidence that those protofibrillar forms of α-
synuclein may be the toxic species in neurons in that 
they destroy lipid membranes. Therefore, it is also a 
possibility that oxidative damage that increases α-
synuclein binding to lipid membranes can lead to toxic 
events in neurons (Figure 2). 
 α-Synuclein has been more concretely linked 
to oxidative stress with its involvement in the JNK 
pathway previously discussed. A study by Hashimoto 
and colleagues revealed that hydrogen peroxide 
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treatment resulted in the activation of the JNK pathway and death in a neuronal cell line. α-Synuclein 
 
 
Figure 2: Oxidative stress can contribute to α-synuclein dysfunction and cell death in PD.  
ROS can damage α-synuclein’s lipid binding ability and contribute to the formation of α-synuclein aggregates. ROS can also damage lipid 
membranes and prevent or promote α-synuclein binding, both events that are hypothesized to cause cell death. 
 
transfection, however, protected against this cell death, 
and JNK was inactivated due to increased expression 
of JNK-interacting protein (JIP). Moreover, α-synuclein 
was shown to co-localize with JIP. This proposes a 
protective role of α-synuclein against oxidative stress 
due to its ability to inactivate the JNK pathway via 
upregulation of JIP (Hashimoto et al., 2002). The 
protective activity of the α-synuclein may decrease if 
the protein is mutated, misfolded, or aggregated, and 
therefore unable to interact with JIP (Figure 1). Further 
studies involving oxidative stress conditions and the 
JNK pathway may bolster the connection between 
pathological forms of α-synuclein and oxidative stress.  
The formation of Lewy bodies within surviving 
nigrostriatal neurons of PD patients (Spillantini et al., 
1997) has led to two theories regarding α-synuclein 
toxicity: aggregates are precursors to cytotoxic events 
in these neurons (Goedert, 1999), or aggregates are 
cytoprotective against smaller toxic forms of misfolded 
α-synuclein (McNaught et al., 2002). A study examining 
dopamine’s interaction with α-synuclein provides 
evidence for the latter. This study revealed that 
dopamine quinones inhibited the fibrillization of α-
synuclein by reacting with the protein’s amino groups to 
form toxic, oligomeric, cross-linked, dopamine-quinone 
adducts (Li et al., 2005). Because oxidative stress 
conditions are conducive to the formation of dopamine 
quinones, this study creates a strong connection 
between dopaminergic neuronal death, α-synuclein, 
and oxidative stress.  
   
 
The function of α-synuclein has also been implicated in 
dopamine transport. Dopamine transporter (DAT) 
facilitates the reuptake of dopamine from the synaptic 
cleft back into the presynpatic neuron (Reith et al., 
1997). α-Synuclein has been shown to bind to DAT and 
assist it in clustering within the membrane to accelerate 
dopamine uptake (Lee et al., 2001). Damaged or 
aggregated α-synuclein may lead to the accumulation 
of dopamine and its subsequent oxidation into harmful 
metabolites, thus increasing oxidative stress. The role 
of α-synuclein in the JNK pathway, lipid binding, and 
dopamine transport all provide hypotheses for its 
involvement with oxidative stress conditions that may 




Although a great deal of progress has been 
made in delineating the mechanisms by which neuronal 
degeneration occurs in PD, there are still many gaps in 
knowledge that plague the field. Oxidative stress is 
undoubtedly a key player in neuronal degeneration in 
PD, but targeting the pathways by which it induces cell 
death cannot be considered until the mechanisms are 
fully understood.  
In reviewing studies that focus on oxidative 
stress and PD, it is apparent that α-synuclein, oxidative 
stress, and apoptosis are all related by complex 
α-synuclein 









ROS       + increased α-synuclein 
binding to damaged 
membrane 
damaged           
α-synuclein 
cannot bind to 
membrane X 
α-synuclein 
+   ROS 






mechanisms that may or may not be linked. Examining 
the effects of PD-inducing agents reveals new findings  
that supports mechanisms by which oxidative stress is 
involved in the activation of specific apoptotic pathways. 
The JNK pathway is seemingly important as DJ-1, 
rotenone, and α-synuclein can all be implicated in the 
activation or inactivation of this pathway, which can 
lead to or prevent apoptosis (Figure 1).  
α-Synuclein, itself, seems to be involved in 
several cellular process due to its lipid binding abilities. 
This study has mentioned two such abilities: its 
association with JIP and its regulation of dopamine 
transport. Because α-synuclein may have several 
functions, it may also be responsible for a great deal of 
cellular dysfunction when damaged (Figures 1 & 2). 
Whether oxidative stress is a cause or effect of α-
synuclein aggregation is a major question that remains 
in the field and must be answered before any therapy 




I would like to thank Dr. Shubhik DebBurman for proposing the 
idea to write this review and for his guidance and collaboration 
that has helped along the way. 
 
Note: Eukaryon is published by students at Lake Forest 
College, who are solely responsible for its content. The 
views expressed in Eukaryon do not necessarily reflect 




Alam, Z.I., Daniel, S.E., Lees, A.J., Marsden, D.C., Jenner, P., and 
Halliwell, B. 1997a. A generalised increase in protein carbonyls in the 
brain in Parkinson's but not incidental Lewy body disease. J Neurochem 
69(3): 1326-9. 
 
Alam, Z.I., Jenner, A., Daniel, S.E., Lees, A.J., Cairns, N., Marsden, C.D., 
Jenner, P., and Halliwell, B. 1997b. Oxidative DNA damage in the 
parkinsonian brain: an apparent selective increase in 8-hydroxyguanine 
levels in substantia nigra. J Neurochem 69(3):1196-203. 
 
Andreassen, O.A., Ferrante, R.J., Dedeoglu, A., Albers, D.W., Klivenyi, P., 
Carlson, E.J., Epstein, C.J., and Beal, M.F. 2001. Mice with a partial 
deficiency of manganese superoxide dismutase show increased 
vulnerability to the mitochondrial toxins malonate, 3-nitropropionic acid, 
and MPTP. Exp Neurol 167(1): 189-95. 
 
Betarbet, R., Sherer, T.B., MacKenzie, G., Garcia-Osuna, M., Panov, A.V., 
and Greenamyre, J.T. 2000. Chronic systemic pesticide exposure 
reproduces features of Parkinson's disease. Nat Neurosci 3(12): 1301-6. 
 
Bonifati, V., Rizzu, P., Squitieri, F., Krieger, E., Vanacore, N., van Swieten, 
J.C., Brice, A., van Duijn, C.M., Oostra, B., Meco, G., and Heutink, P. 
2003. DJ-1( PARK7), a novel gene for autosomal recessive, early onset 
parkinsonism. Neurol Sci 24(3): 159-60. 
 
Bowling, A.C., and Beal, M.F. 1995. Bioenergetic and oxidative stress in 
neurodegenerative diseases. Life Sci 56(14): 1151-71. 
 
Bretaud, S., Lee, S., and Guo, S. 2004. Sensitivity of zebrafish to 
environmental toxins implicated in Parkinson's disease. Neurotoxicol 
Teratol 26(6): 857-64. 
 
Brooks, A.I., Chadwick, C.A., Gelbard, H.A., Cory-Slechta, D.A., and 
Federoff, H.J. 1999. Paraquat elicited neurobehavioral syndrome caused 
by dopaminergic neuron loss. Brain Res 823(1-2): 1-10. 
 
Burns, R.S., Chiueh, C.C., Markey, S.P., Ebert, M.H., Jacobowitz, D.M., 
and Kopin, I.J. 1983. A primate model of parkinsonism: selective 
destruction of dopaminergic neurons in the pars compacta of the 
substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. PNAS 
80(14): 4546-50. 
 
Carrasco, E., Casper, D., and Werner, P. 2005. Dopaminergic 
neurotoxicity by 6-OHDA and MPP+: differential requirement for neuronal 
cyclooxygenase activity. Journal of Neuroscience Research 81(1): 121-31. 
 
Casper, D., Yaparpalvi, U., Rempel, N., and Werner, P. 2000. Ibuprofen 
protects dopaminergic neurons against glutamate toxicity in vitro. 
Neuroscience Letters 289(3): 201-4. 
 
Chen, H., Jacobs, E., Schwarzschild, M.A., McCullough, M.L., Calle, E.E., 
Thun, M.J., and Ascherio, A. 2005. Nonsteroidal antiinflammatory drug 
use and the risk for Parkinson's disease. Annals of Neurology [Epub 
ahead of print]. 
 
Corasaniti, M.T., Bagetta, G., Rodino, P., Gratteri, S., and Nistico, G. 
1992. Neurotoxic effects induced by intracerebral and systemic injection of 
paraquat in rats. Hum Exp Toxicol 11(6): 535-9. 
Coulom, H., and Birman, S. 2004. Chronic exposure to rotenone models 
sporadic Parkinson's disease in Drosophila melanogaster. J Neurosci 
24(48): 10993-8. 
 
Dauer, W., and Przedborski, S. 2003. Parkinson's disease: mechanisms 
and models. Neuron 39(6): 889-909. 
 
Davidson, W.S., Jonas, A., Clayton, D.F., and George, J.M. 1998. 
Stabilization of alpha-synuclein secondary structure upon binding to 
synthetic membranes. J Biol Chem 273(16): 9443-9. 
 
Delacourte, A., Defossez, A., Ceballos, I., Nicole, A., and Sinet, P.M. 
1988. Preferential localization of copper zinc superoxide dismutase in the 
vulnerable cortical neurons in Alzheimer's disease. Neurosci Letters 92(3): 
247-53. 
 
Dexter, D., Carter, C., Agid, F., Agid, Y., Lees, A.J., Jenner, P., and 
Marsden, C.D. 1986. Lipid peroxidation as cause of nigral cell death in 
Parkinson's disease. Lancet 2(8507): 639-40. 
 
Eliezer, D., Kutluay, E., Bussell, R. Jr., and Browne, G. 2001. 
Conformational properties of alpha-synuclein in its free and lipid-
associated states. J Mol Biol 307(4): 1061-73. 
 
Farin, F.M., Hitosis, Y., Hallagan, S.E., Kushleika, J., Woods, J.S., 
Janssen, P.S., Smith-Weller, T., Franklin, G.M., Swanson, P.D., and 
Checkoway, H. 2001. Genetic polymorphisms of superoxide dismutase in 
Parkinson's disease. Mov Disord 16(4): 705-7. 
 
Goedert, M. 1999. Filamentous nerve cell inclusions in neurodegenerative 
diseases: tauopathies and alpha-synucleinopathies. Philosophical 
transactions of the Royal Society of London. Series B, Biological sciences 
354(1386): 1101-18. 
 
Hartley, A., Stone, J.M., Heron, C., Cooper, J.M., and Schapira, A.H. 
1994. Complex I inhibitors induce dose-dependent apoptosis in PC12 
cells: relevance to Parkinson's disease. J Neurochem 63(5): 1987-90. 
 
Hashimoto, M., Hsu, L.J., Rockenstein, E., Takenouchi, T., Mallory, M., 
and Masliah, E. 2002. alpha-Synuclein protects against oxidative stress 
via inactivation of the c-Jun N-terminal kinase stress-signaling pathway in 
neuronal cells. J Biol Chem 277(13): 11465-72. Epub 2002 Jan 14. 
 
Hastings, T.G., and Zigmond, M.J. 1997. Loss of dopaminergic neurons in 
parkinsonism: possible role of reactive dopamine metabolites. J Neural 
Transm Suppl 49: 103-10. 
 
Heikkila, R.E., and Cohen, G. 1973. 6-Hydroxydopamine: evidence for 
superoxide radical as an oxidative intermediate. Science 181(98): 456-7. 
 
Hinerfeld, D., Traini, M.D., Weinberger, R.P., Cochran, B., Doctrow, S.R., 
Harry, J., and Melov, S. 2004. Endogenous mitochondrial oxidative stress: 
neurodegeneration, proteomic analysis, specific respiratory chain defects, 
and efficacious antioxidant therapy in superoxide dismutase 2 null mice. J 
Neurochem 88(3): 657-67. 
 
Jaattela, M., Benedict, M., Tewari, M., Shayman, J.A., and Dixit, V.M. 
1995. Bcl-x and Bcl-2 inhibit TNF and Fas-induced apoptosis and 
activation of phospholipase A2 in breast carcinoma cells. Oncogene 
10(12): 2297-305. 
 
Javoy, F., Sotelo, C., Herbet, A., and Agid, Y. 1976. Specificity of 
dopaminergic neuronal degeneration induced by intracerebral injection of 
6-hydroxydopamine in the nigrostriatal dopamine system. Brain Res 
102(2): 201-15.  
 
Jones, A.C., Yamamura, Y., Almasy, L., Bohlega, S., Elibol, B., Hubble, J., 
Kuzuhara, S., Uchida, M., Yanagi, T., Weeks, D.E., and Nygaard, T.G. 
1998. Autosomal recessive juvenile parkinsonism maps to 6q25.2-q27 in 
four ethnic groups: detailed genetic mapping of the linked region. Am J 
Hum Genet 63(1): 80-7. 
 
Junn, E., Taniguchi, H., Jeong, B.S., Zhao, X., Ichijo, H., and Mouradian, 
M.M. 2005. Interaction of DJ-1 with Daxx inhibits apoptosis signal-
regulating kinase 1 activity and cell death. PNAS 102(27): 9691-6. Epub 
2005 Jun 27. 
 
Kim, K.S., Hwang, H.A., Chae, S.K., Ha, H., and Kwon, K.S. 2005. 
Upregulation of Daxx mediates apoptosis in response to oxidative stress. 
J Cell Biochem 96(2): 330-8. 
 
Kitayama, S., Shimada, S., and Uhl, G.R. 1992. Parkinsonism-inducing 
neurotoxin MPP+: uptake and toxicity in nonneuronal COS cells 
expressing dopamine transporter cDNA. Ann Neurol 32(1): 109-11. 
 
 27 
Kitayama, S., Wang, J.B., and Uhl, G.R. 1993. Dopamine transporter 
mutants selectively enhance MPP+ transport. Synapse 15(1): 58-62. 
Knott, C., Stern, G., and Wilkin, G.P. 2000. Inflammatory regulators in 
Parkinson's disease: iNOS, lipocortin-1, and cyclooxygenases-1 and -2. 
Molecular and Cellular Neurosciences 16(6): 724-39. 
 
Krueger, M.J., Singer, T.P., Casida, J.E., and Ramsay, R.R. 1990. 
Evidence that the blockade of mitochondrial respiration by the neurotoxin 
1-methyl-4-phenylpyridinium (MPP+) involves binding at the same site as 
the respiratory inhibitor, rotenone. Biochem Biophys Res Commun 169(1): 
123-8.  
  
Kweon, G.R., Marks, J.D., Krencik, R., Leung, E.H., Schumacker, P.T., 
Hyland, K., and Kang, U.J. 2004. Distinct mechanisms of 
neurodegeneration induced by chronic complex I inhibition in 
dopaminergic and non-dopaminergic cells. J Biol Chem 279(50): 51783-
92. Epub 2004 Oct 6. 
 
Lee, F.J., Liu, F., Pristupa, Z.B., and Niznik, H.B. 2001. Direct binding and 
functional coupling of alpha-synuclein to the dopamine transporters 
accelerate dopamine-induced apoptosis. FASEB J 15(6): 916-26. 
 
Li, H.T., Lin, D.H., Luo, X.Y., Zhang, F., Ji, L.N., Du, H.N., Song, G.Q., Hu, 
J., Zhou, J.W., and Hu, H.Y. 2005. Inhibition of alpha-synuclein 
fibrillization by dopamine analogs via reaction with the amino groups of 
alpha-synuclein. Implication for dopaminergic neurodegeneration. FEBS J 
272(14): 3661-72. 
 
Li, X., and Sun, A.Y. 1999. Paraquat induced activation of transcription 
factor AP-1 and apoptosis in PC12 cells. J Neural Transm 106(1): 1-21. 
 
McDaniel ML, Kwon G, Hill JR, Marshall CA, Corbett JA. Cytokines and 
nitric oxide in islet inflammation and diabetes. Proceedings of the Society 
for Experimental Biology and Medicine. Society for Experimental Biology 
and Medicine. 1996 Jan;211(1):24-32. 
 
McNaught, K.S., Shashidharan, P., Perl, D.P., Jenner, P., and Olanow, 
C.W. 2002. Aggresome-related biogenesis of Lewy bodies. Eur J Neurosci 
16(11): 2136-48. 
 
Mendez, J.S., and Finn, B.W. 1975. Use of 6-hydroxydopamine to create 
lesions in catecholamine neurons in rats. J Neurosurg 42(2): 166-73. 
 
Mizuno, Y., Ohta, S., Tanaka, M., Takamiya, S., Suzuki, K., Sato, T., Oya, 
H., Ozawa, T., and Kagawa, Y. 1989. Deficiencies in complex I subunits of 
the respiratory chain in Parkinson's disease. Biochem Biophys Res 
Commun 163(3): 1450-5. 
 
Nishinaga, H., Takahashi-Niki, K., Taira, T., Andreadis, A., Iguchi-Ariga, 
S.M., and Ariga, H. 2005. Expression profiles of genes in DJ-1-knockdown 
and L 166 P DJ-1 mutant cells. Neurosci Letters 390(1): 54-9. 
 
Olanow, C.W., and Tatton, W.G. 1999. Etiology and pathogenesis of 
Parkinson's disease. Annu Rev Neurosci 22: 123-44. 
 
Outeiro, T.F., and Lindquist, S. 2003. Yeast cells provide insight into 
alpha-synuclein biology and pathobiology. Science 302(5651): 1772-5. 
 
Parker, W.D. Jr, Boyson, S.J., and Parks, J.K. 1989. Abnormalities of the 
electron transport chain in idiopathic Parkinson's disease. Annals of 
Neurology 26(6): 719-23. 
 
Rae, T.D., Schmidt, P.J., Pufahl, R.A., Culotta, V.C., and O'Halloran, T.V. 
1999. Undetectable intracellular free copper: the requirement of a copper 
chaperone for superoxide dismutase. Science 284(5415): 805-8. 
 
Ramsay, R.R., Krueger, M.J., Youngster, S.K., Gluck, M.R., Casida, J.E., 
and Singer, T.P. 1991. Interaction of 1-methyl-4-phenylpyridinium ion 
(MPP+) and its analogs with the rotenone/piericidin binding site of NADH 
dehydrogenase. J Neurochem 56(4): 1184-90. 
 
Reith, M.E., Xu, C., and Chen, N.H. 1997. Pharmacology and regulation of 
the neuronal dopamine transporter. Eur J Pharmacol 324(1): 1-10. 
 
Rosen, D.R., Siddique, T., Patterson, D., Figlewicz, D.A., Sapp, P., 
Hentati, A., Donaldson, D., Goto, J., O'Regan, J.P., and Deng, H.X. 1993. 
Mutations in Cu/Zn superoxide dismutase gene are associated with 
familial amyotrophic lateral sclerosis. Nature 362(6415): 59-62. 
 
Sahgal, A., Andrews, J.S., Biggins, J.A., Candy, J.M., Edwardson, J.A., 
Keith, A.B., Turner, J.D., and Wright, C. 1984. N-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP) affects locomotor activity without producing a 
nigrostriatal lesion in the rat. Neurosci Letters 48(2): 179-84. 
 
Schapira, A.H., Cooper, J.M., Dexter, D., Jenner, P., Clark, J.B., and 
Marsden, C.D. 1989. Mitochondrial complex I deficiency in Parkinson's 
disease. Lancet 1(8649): 1269. 
 
Sharon, R., Goldberg, M.S., Bar-Josef, I., Betensky, R.A., Shen, J., and 
Selkoe, D.J. 2001. alpha-Synuclein occurs in lipid-rich high molecular 
weight complexes, binds fatty acids, and shows homology to the fatty 
acid-binding proteins. PNAS 98(16): 9110-5. 
 
Sherer, T.B., Betarbet, R., Stout, A.K., Lund, S., Baptista, M., Panov, A.V., 
Cookson, M.R., and Greenamyre, J.T. 2002. An in vitro model of 
Parkinson's disease: linking mitochondrial impairment to altered alpha-
synuclein metabolism and oxidative damage. J Neurosci 22(16): 7006-15. 
 
Simantov, R., Blinder, E., Ratovitski, T., Tauber, M., Gabbay, M., and 
Porat, S. 1996. Dopamine-induced apoptosis in human neuronal cells: 
inhibition by nucleic acids antisense to the dopamine transporter. 
Neuroscience 74(1): 39-50. 
 
Singer, T.P., Castagnoli, N. Jr,, Ramsay, R.R., and Trevor, A.J. 1987. 
Biochemical events in the development of parkinsonism induced by 1-
methyl-4-phenyl-1,2,3,6-tetrahydropyridine. J Neurochem 49(1): 1-8. 
 
Slivka, A., and Cohen, G. 1985. Hydroxyl radical attack on dopamine. J 
Biol Chem 260(29): 15466-72. 
 
Slot, J.W., Geuze, H.J., Freeman, B.A., and Crapo, J.D. 1986. Intracellular 
localization of the copper-zinc and manganese superoxide dismutases in 
rat liver parenchymal cells. Lab Invest 55(3): 363-71. 
 
Spillantini, M.G., Schmidt, M.L., Lee, V.M., Trojanowski, J.Q., Jakes, R., 
and Goedert, M. Alpha-synuclein in Lewy bodies. Nature 388(6645): 839-
40. 
 
Sundstrom, E., Fredriksson, A., and Archer, T. 1990. Chronic 
neurochemical and behavioral changes in MPTP-lesioned C57BL/6 mice: 
a model for Parkinson's disease. Brain Res 528(2): 181-8. 
 
Taira, T., Saito, Y., Niki, T., Iguchi-Ariga, S.M., Takahashi, K., and Ariga, 
H. 2004. DJ-1 has a role in antioxidative stress to prevent cell death. 
EMBO Rep 5(2): 213-8. Epub 2004 Jan 23. 
 
Volles, M.J., Lee, S.J., Rochet, J.C., Shtilerman, M.D., Ding, T.T., Kessler, 
J.C., and Lansbury, P.T. Jr. 2001. Vesicle permeabilization by protofibrillar 
alpha-synuclein: implications for the pathogenesis and treatment of 
Parkinson's disease. Biochemistry 40(26): 7812-78129. 
 
Watabe, M., and Nakaki, T. 2004. Rotenone induces apoptosis via 
activation of bad in human dopaminergic SH-SY5Y cells. J Pharmacol Exp 
Ther 311(3): 948-53. Epub 2004 Jul 27. 
 
Willingham, S., Outeiro, T.F., DeVit, M.J., Lindquist, S.L., and Muchowski, 
P.J. 2003. Yeast genes that enhance the toxicity of a mutant huntingtin 
fragment or alpha-synuclein. Science 302(5651): 1769-72. 
 
Wu, Y., Blum, D., Nissou, M.F., Benabid, A.L., and Verna, J.M. 1996. 
Unlike MPP+, apoptosis induced by 6-OHDA in PC12 cells is independent 
of mitochondrial inhibition. Neuroscience Letters 221(1): 69-71. 
 
Yang, E., Zha, J., Jockel, J., Boise, L.H., Thompson, C.B., and 
Korsmeyer, S.J. 1995. Bad, a heterodimeric partner for Bcl-XL and Bcl-2, 
displaces Bax and promotes cell death. Cell 80(2): 285-91. 
 
Yang, X., Khosravi-Far, R., Chang, H.Y., and Baltimore, D. 1997. Daxx, a 
novel Fas-binding protein that activates JNK and apoptosis. Cell 89(7): 
1067-76. 
 
Zhou, W., and Freed, C.R. 2005. DJ-1 upregulates glutathione synthesis 
during oxidative stress and inhibits A53T alpha -synuclein toxicity. J Biol 
Chem. [Epub ahead of print].  
 
